Literature DB >> 30124146

Emerging and Alternative Therapies For Parkinson Disease: An Updated Review.

Atul Kabra1,2, Rohit Sharma3, Ruchika Kabra2, Uttam Singh Baghel1,2.   

Abstract

Parkinson's disease (PD) is standout amongst the most common neurodegenerative malady with unpredictable dynamic pathology. At present, accessible traditional choices for PD have certain impediments of their own, and subsequently persistent consistence and fulfillment are low. Current contemporary treatment options just give symptomatic alleviation constrained control to anticipate malady progression, bringing about poor patient consistence and fulfilment. Numerous rising pharmacotherapies for PD are in various phases of medical improvement. Treatments incorporate adenosine A2A receptor antagonists, anti-apoptotic agents, monoamine oxidase inhibitors, glutamate receptor antagonists, and antioxidants for example, N-acetyl cysteine, edaravone, and coenzyme Q10. Other rising nonpharmacotherapies incorporate microRNAs, viral vector gene therapy, stem cells transglutaminases, RTP801, and glial derived neurotrophic factor (GDNF). Furthermore, surgeries including profound pallidotomy, deep brain stimulation, thalamotomy and gamma knife surgery have developed as elective mediations for cutting edge PD patients who have totally used common medications and still suffer from unrelenting motor symptoms. Complementary and Alternative medicine (CAM) modalities, such as Yoga, acupuncture, Tai Chi, Music therapies are highly practiced in several countries, offer some of the safer and effective treatment modalities for PD. While a few of these treatments hold much assurance in postponing the beginning of ailment and moderating its progression, more pharmacotherapies and careful mediations should be examined in various phases of PD. Therefore, the main objective of our review is to fill the gap between the researches and provide updated and productive information about the research reported in the last couple of years and can fulfil the most reassuring plausibility for encourage treatment of Parkinson Disease. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Ayurveda; Parkinson disease; alternative medicine; depression; dopamine; pharmacotherapies.

Mesh:

Substances:

Year:  2018        PMID: 30124146     DOI: 10.2174/1381612824666180820150150

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  11 in total

1.  Impact of Auditory Integration Therapy (AIT) on the Plasma Levels of Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) in Autism Spectrum Disorder.

Authors:  Laila Al-Ayadhi; Afaf El-Ansary; Geir Bjørklund; Salvatore Chirumbolo; Gehan Ahmed Mostafa
Journal:  J Mol Neurosci       Date:  2019-05-09       Impact factor: 3.444

2.  Roflupram protects against rotenone-induced neurotoxicity and facilitates α-synuclein degradation in Parkinson's disease models.

Authors:  Wen-Li Dong; Jia-Hong Zhong; Yun-Qing Chen; Jin-Feng Xie; Yun-Yun Qin; Jiang-Ping Xu; Ning-Bo Cai; Meng-Fan Li; Lu Liu; Hai-Tao Wang
Journal:  Acta Pharmacol Sin       Date:  2021-09-16       Impact factor: 6.150

Review 3.  MALAT1 lncRNA and Parkinson's Disease: The role in the Pathophysiology and Significance for Diagnostic and Therapeutic Approaches.

Authors:  M Abrishamdar; M S Jalali; M Rashno
Journal:  Mol Neurobiol       Date:  2022-06-04       Impact factor: 5.682

4.  Epothilone B prevents lipopolysaccharide-induced inflammatory osteolysis through suppressing osteoclastogenesis via STAT3 signaling pathway.

Authors:  Yueqi Chen; Yiran Wang; Junxian Hu; Yong Tang; Zhansong Tian; Wenhui Hu; Fanchun Zeng; Jiulin Tan; Qijie Dai; Zhiyong Hou; Fei Luo; Jianzhong Xu; Shiwu Dong
Journal:  Aging (Albany NY)       Date:  2020-06-11       Impact factor: 5.682

5.  Epothilone B Benefits Nigral Dopaminergic Neurons by Attenuating Microglia Activation in the 6-Hydroxydopamine Lesion Mouse Model of Parkinson's Disease.

Authors:  Zhongyuan Yu; Ling Yang; Yang Yang; Siyu Chen; Dayu Sun; Haiwei Xu; Xiaotang Fan
Journal:  Front Cell Neurosci       Date:  2018-09-28       Impact factor: 5.505

6.  Long non-coding RNA MALAT1 regulates cell proliferation and apoptosis via miR-135b-5p/GPNMB axis in Parkinson's disease cell model.

Authors:  Kefeng Lv; Yuhua Liu; Yanbing Zheng; Shaowen Dai; Peifeng Yin; Haifeng Miao
Journal:  Biol Res       Date:  2021-03-16       Impact factor: 5.612

7.  Acupuncture Therapy for Cognitive Impairment: A Delphi Expert Consensus Survey.

Authors:  Xin-Tong Su; Li-Qiong Wang; Jin-Ling Li; Na Zhang; Lu Wang; Guang-Xia Shi; Jing-Wen Yang; Cun-Zhi Liu
Journal:  Front Aging Neurosci       Date:  2020-11-26       Impact factor: 5.750

8.  Retracted Article: LncRNA MALAT1 aggravates MPP-induced neuronal injury by regulating miR-212 in SH-SY5Y cells.

Authors:  Dahua Yuan; Qun Wang; Nan Ding; Pu Du; Lingmei Peng; Zhenpeng Duan; Suyue Pan
Journal:  RSC Adv       Date:  2019-01-04       Impact factor: 4.036

9.  Protective effect of hydroxysafflor yellow A on dopaminergic neurons against 6-hydroxydopamine, activating anti-apoptotic and anti-neuroinflammatory pathways.

Authors:  Xiaomei Yang; Yun Li; Lin Chen; Mingguo Xu; Jianbo Wu; Peng Zhang; Deon Nel; Baozhu Sun
Journal:  Pharm Biol       Date:  2020-12       Impact factor: 3.503

10.  Comparison of efficacy and safety of complementary and alternative therapies for Parkinson's disease: A Bayesian network meta-analysis protocol.

Authors:  Chuancheng Li; Hongqiang An; Jiahao Wang; Zhenyuan Jiang; Tianqi Zhang; Qing Huo
Journal:  Medicine (Baltimore)       Date:  2020-09-18       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.